US FDA Approves VAXNEUVANCE Of Merck To Treat Invasive Pneumococcal Disease
Merck announced that, the Food and Drug Administration (FDA) of the United States has approved an expanded indication for the VAXNEUVANCE for treating the invasive pneumococcal disease in the children between 6 weeks to 17 years of age. The VAXNEUVANCE is now indicated for the active immunization for the prevention of the invasive disease, which […]
Continue Reading